🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

57 results for “Theravance” Clear

  1. Ampreloxetine <Dose A>

    Theravance Biopharma Ireland Umited

    Symptomatic Neurogenic Orthostatic Hypertension

    phase 1 small molecule completed

    1 trial

  2. GSK961081

    Theravance Biopharma Ireland Umited

    Pulmonary Disease, Chronic Obstructive

    phase 1 small molecule completed

    2 trials

  3. GSK961081 15mcg SD

    Theravance Biopharma Ireland Umited

    Pulmonary Disease, Chronic Obstructive

    phase 1 small molecule completed

    1 trial

  4. Nezulcitinib (TD-0903) Dose A

    Theravance Biopharma Ireland Umited

    Acute Lung Injury (ALI) Due to Coronavirus Disease-2019 (COVID-19)

    phase 1 small molecule completed

    1 trial

  5. TD-0714

    Theravance Biopharma Ireland Umited

    Healthy Adults, Elderly Subjects

    phase 1 small molecule completed

    1 trial

  6. TD-0714

    Theravance Biopharma Ireland Umited

    Healthy

    phase 1 small molecule completed

    1 trial

  7. TD-1058

    Theravance Biopharma Ireland Umited

    Idiopathic Pulmonary Fibrosis (IPF)

    phase 1 small molecule terminated

    1 trial

  8. TD-1211 Dose 1

    Theravance Biopharma Ireland Umited

    Constipation

    phase 1 small molecule completed

    1 trial

  9. TD-1439

    Theravance Biopharma Ireland Umited

    Healthy Subjects

    phase 1 small molecule completed

    1 trial

  10. TD-1439

    Theravance Biopharma Ireland Umited

    Healthy Adults, Elderly Subjects

    phase 1 small molecule completed

    1 trial

  11. TD-1473

    Theravance Biopharma Ireland Umited

    Ulcerative Colitis, Active Moderate

    phase 1 small molecule completed

    1 trial

  12. TD-1473

    Theravance Biopharma Ireland Umited

    Inflammatory Bowel Disease

    phase 1 small molecule completed

    1 trial

  13. TD-1473 - Dose A

    Theravance Biopharma Ireland Umited

    Inflammatory Bowel Diseases

    phase 1 small molecule completed

    1 trial

  14. TD-1473 [Tablet A]

    Theravance Biopharma Ireland Umited

    Intestinal Disorder

    phase 1 small molecule completed

    1 trial

  15. TD-1473 for SAD

    Theravance Biopharma Ireland Umited

    Healthy

    phase 1 small molecule completed

    1 trial

  16. TD-1473 oral capsule

    Theravance Biopharma Ireland Umited

    Intestinal Disorders

    phase 1 small molecule completed

    1 trial

  17. TD-1607

    Theravance Biopharma Ireland Umited

    Infections

    phase 1 small molecule completed

    1 trial

  18. TD-1607

    Theravance Biopharma Ireland Umited

    Serious Infections Due to Known or Suspected Gram-positive Pathogens

    phase 1 small molecule completed

    1 trial

  19. TD-3504

    Theravance Biopharma Ireland Umited

    Active Mild Ulcerative Colitis, Active Moderate Ulcerative Colitis, Healthy Subjects

    phase 1 small molecule completed

    1 trial

  20. TD-4208

    Theravance Biopharma Ireland Umited

    Hepatic Impairment

    phase 1 small molecule completed

    1 trial

  21. TD-4208

    Theravance Biopharma Ireland Umited

    Renal Impairment

    phase 1 small molecule completed

    1 trial

  22. TD-4208 175 mcg

    Theravance Biopharma Ireland Umited

    Cardiac Repolarization in Healthy Subjects

    phase 1 small molecule completed

    1 trial

  23. TD-5202

    Theravance Biopharma Ireland Umited

    Healthy

    phase 1 small molecule completed

    1 trial

  24. TD-6450

    Theravance Biopharma Ireland Umited

    Hepatitis C

    phase 1 small molecule completed

    2 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources